A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2018

At a glance

  • Drugs Apalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SPARTAN
  • Sponsors Aragon Pharmaceuticals; Janssen Pharmaceutical KK
  • Most Recent Events

    • 11 Sep 2018 Albania, Ireland, Italy, Jersey were the planned locations for this study.
    • 11 Sep 2018 According to a Janssen Pharmaceuticals media release, Fred Saad is a investigator and author of the study.
    • 11 Sep 2018 According to a Janssen Pharmaceuticals media release, patient-reported outcomes (PRO) data were published in The Lancet Oncology 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top